MedTrace Logo

Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians

NCT06315478 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-03-18

No results posted yet for this study

Summary

Our study aimed to investigate the efficacy and safety of hybrid regimen as a first line therapy for H. pylori eradication compared to triple and quadruple regimens in attempt to overcome antibiotic resistance

Conditions

  • H.Pylori Infection

Interventions

DRUG

Omeprazole 20 MG Oral Tablet

standard triple therapy for 14 days Bid for each drug

DRUG

Amoxicillin 500Mg Tab

Quadruple regimen for 14 days Bid for each drug

DRUG

Clarithromycin 500Mg Tab

Hybrid regimen, PPI and Amoxicillin for first 7 days then adding clarithromycin and metronidazole for the second 7 days

Sponsors & Collaborators

  • Helwan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-03-16
Completion
2021-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06315478 on ClinicalTrials.gov